Christine Bellon

CIK: 0001963878

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)11 (64.7%)

Position reduction

Option Exercises (M)2 (11.8%)

Derivative conversions

Awards (A)4 (23.5%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

BEAM

Beam Therapeutics Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (17 total)

BEAM
Beam Therapeutics Inc.
Apr 1, 2026
Sale(S)
Direct
6K shares at avg. $24.58$146K
BEAM
Beam Therapeutics Inc.
Mar 31, 2026
Award(A)
Direct
20K shares-
BEAM
Beam Therapeutics Inc.
Jan 31, 2026
Award(A)
Stock Option (Right to Buy)
Direct
40K shares-
BEAM
Beam Therapeutics Inc.
Jan 22, 2026
Sale(S)
Direct
1.4K shares at avg. $34.00$47K
BEAM
Beam Therapeutics Inc.
Jan 15, 2026
Sale(S)
Direct
559 shares at avg. $35.40$20K
BEAM
Beam Therapeutics Inc.
Jan 15, 2026
Sale(S)
Direct
16K shares at avg. $34.72$554K
BEAM
Beam Therapeutics Inc.
Jan 15, 2026
Sale(S)
Direct
2.1K shares at avg. $33.62$71K
BEAM
Beam Therapeutics Inc.
Dec 31, 2025
Sale(S)
Direct
1.3K shares at avg. $27.10$34K
BEAM
Beam Therapeutics Inc.
Oct 1, 2025
Sale(S)
Direct
373 shares at avg. $24.53$9K
BEAM
Beam Therapeutics Inc.
Apr 1, 2025
Sale(S)
Direct
5.7K shares at avg. $18.35$104K
BEAM
Beam Therapeutics Inc.
Mar 31, 2025
Award(A)
Direct
20K shares-
BEAM
Beam Therapeutics Inc.
Feb 14, 2025
Exercise(M)
Direct
9.5K shares at avg. $7.22$69K
BEAM
Beam Therapeutics Inc.
Feb 14, 2025
Exercise(M)
Direct
508 shares at avg. $7.22$4K
BEAM
Beam Therapeutics Inc.
Feb 14, 2025
Sale(S)
Direct
10K shares at avg. $34.00$340K
BEAM
Beam Therapeutics Inc.
Jan 31, 2025
Award(A)
Stock Option (Right to Buy)
Direct
40K shares-
BEAM
Beam Therapeutics Inc.
Jan 2, 2025
Sale(S)
Direct
1.2K shares at avg. $24.68$31K
BEAM
Beam Therapeutics Inc.
Oct 1, 2024
Sale(S)
Direct
385 shares at avg. $23.48$9K

		Type	Shares	Price		Ownership
Apr 1, 2026	BEAM Beam Therapeutics Inc.	Sale(S)	5,956	$24.58	$146,398	Direct
Mar 31, 2026	BEAM Beam Therapeutics Inc.	Award(A)	20,000	-	$0	Direct
Jan 31, 2026	BEAM Beam Therapeutics Inc.	Award(A) Stock Option (Right to Buy)	40,000	-	-	Direct
Jan 22, 2026	BEAM Beam Therapeutics Inc.	Sale(S)	1,371	$34.00	$46,614	Direct
Jan 15, 2026	BEAM Beam Therapeutics Inc.	Sale(S)	559	$35.40	$19,788	Direct
Jan 15, 2026	BEAM Beam Therapeutics Inc.	Sale(S)	15,959	$34.72	$554,068	Direct
Jan 15, 2026	BEAM Beam Therapeutics Inc.	Sale(S)	2,111	$33.62	$70,976	Direct
Dec 31, 2025	BEAM Beam Therapeutics Inc.	Sale(S)	1,254	$27.10	$33,983	Direct
Oct 1, 2025	BEAM Beam Therapeutics Inc.	Sale(S)	373	$24.53	$9,150	Direct
Apr 1, 2025	BEAM Beam Therapeutics Inc.	Sale(S)	5,674	$18.35	$104,122	Direct
Mar 31, 2025	BEAM Beam Therapeutics Inc.	Award(A)	20,000	-	-	Direct
Feb 14, 2025	BEAM Beam Therapeutics Inc.	Exercise(M)	9,492	$7.22	$68,532	Direct
Feb 14, 2025	BEAM Beam Therapeutics Inc.	Exercise(M)	508	$7.22	$3,668	Direct
Feb 14, 2025	BEAM Beam Therapeutics Inc.	Sale(S)	10,000	$34.00	$340,000	Direct
Jan 31, 2025	BEAM Beam Therapeutics Inc.	Award(A) Stock Option (Right to Buy)	40,000	-	-	Direct
Jan 2, 2025	BEAM Beam Therapeutics Inc.	Sale(S)	1,241	$24.68	$30,628	Direct
Oct 1, 2024	BEAM Beam Therapeutics Inc.	Sale(S)	385	$23.48	$9,040	Direct

1-17 of 17 transactions

About Bellon Christine

Bellon Christine (SEC CIK 0001963878) files insider reports with the SEC as Chief Legal Officer of Beam Therapeutics Inc. (BEAM).

Signal8 holds 13 ownership filings by Bellon Christine, all Form 4s, filed between Oct 2, 2024 and Apr 6, 2026. Those filings report 17 transactions, from Oct 1, 2024 to Apr 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Bellon Christine's filings is in CAMBRIDGE, MA.

Recent filings by Bellon Christine

Apr 1, 2026: Open-market sale of BEAM shares (Form 4, code S).
Mar 31, 2026: Grant or award of BEAM shares (Form 4, code A).
Jan 31, 2026: Grant or award of BEAM derivative securities (Form 4, code A).
Jan 22, 2026: Open-market sale of BEAM shares (Form 4, code S).
Jan 15, 2026: Open-market sales of BEAM shares (3 lines, Form 4, code S).

Other insiders filing for Beam Therapeutics Inc. (BEAM)

Evans John M., CEO
Cavanagh Bethany J, SVP, Finance and Treasurer
Ciaramella Giuseppe, President
Simon Amy, Chief Medical Officer
FMR LLC, 10% Owner
Shaw Christi, Director

How to read Form 4 transaction codes